Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.61 |
| ▸ | ELANE | P08246 | 2/20 | 0.60 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632886 | 0.83 | BCL2 (0.67) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL705681 | 0.83 | BCL2 (0.67) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL16227000 | 0.82 | SLC37A4 (0.58) | BCL2MCL1ELANECTSGALDH1A1 | |
| SCHEMBL30038906 | 0.78 | BCL2 (0.59) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL17867273 | 0.78 | BCL2 (0.64) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL16227056 | 0.78 | BCL2 (0.59) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL31139082 | 0.78 | BCL2 (0.59) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL555230 | 0.77 | BCL2 (1.00) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL29384381 | 0.77 | BCL2 (1.00) | BCL2MCL1ELANEMAPK1ALDH1A1 | |
| SCHEMBL29388375 | 0.77 | BCL2 (1.00) | BCL2MCL1ELANEMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | BCL2 2450/4885MCL1 2381/4885ELANE 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.